Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00885196 · ClinicalTrials.gov registry record · Phase 2
A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 336
- Enrollment target
NCT00885196 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 336 participants.
The verdict
NCT00885196, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 336 participants
- Enrollment target
Study Summary
This study is designed to provide efficacy and safety data of several doses of AEB071 so that the optimal dose and treatment duration can be chosen for testing in later studies in patients with plaque psoriasis (with a disease severity such that systemic treatment is justified). The treatment free Follow-up Period is designed to provide additional safety data and information on disease recurrence after the last dose of the study drug.
Interventions
- DRUG Placebo
- DRUG AEB071
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00885196
The ClinicalTrials.gov registry entry for NCT00885196 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 336 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00885196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00885196 about?
NCT00885196 is a clinical study titled "A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis". This study is designed to provide efficacy and safety data of several doses of AEB071 so that the optimal dose and treatment duration can be chosen for testing in later studies in patients with plaque psoriasis (with a disease severity such that systemic treatment is justified). The treatment free F...
What is the current status of trial NCT00885196?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 336 participants. The study started on 2009-04.
What interventions are being tested in trial NCT00885196?
The interventions under investigation include: Placebo (DRUG), AEB071 (DRUG).
Who is sponsoring clinical trial NCT00885196?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.